Search

for
Search:

Learn

0 / 0 results

— no results

Research

5 / 1000+ results

A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

research A Summary of In Vitro, Phase I, and Phase II Studies Evaluating the Mechanism of Action, Safety, and Efficacy of Clascoterone (Cortexolone 17a Propionate, CB-03-01) in Androgenetic Alopecia

3 citations, August 2019 in “Journal of The American Academy of Dermatology”

Clascoterone safely promotes hair growth similar to minoxidil.

research Biotechs Target Stagnant Baldness Market

3 citations, February 2016 in “Nature Biotechnology”

New drug shows promise for better hair growth in baldness treatment.

research Male Pattern Baldness: Causes, Treatments, and Future Prospects

May 2011 in “Prime”

Most American men experience hair loss by age 50, with limited effective treatments available and new options not expected soon.

research A Comprehensive Review on Deep Eutectic Solvents and Their Use to Extract Bioactive Compounds of Pharmaceutical Interest

2 citations, January 2024 in “Pharmaceuticals”

Deep eutectic solvents are eco-friendly and effective for extracting useful pharmaceutical compounds.

research Hair Restoration in Androgenetic Alopecia: Looking Beyond Minoxidil, Finasteride, and Hair Transplantation

13 citations, January 2016 in “Journal of cosmetology & trichology”

Alternative treatments show promise for hair growth beyond traditional methods.

View more "cosmo pharmaceuticals" in research →

Community Join

5 / 49 results

community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!

in Product 51 upvotes 1 year ago

Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.

community Brief update clascoterone phase 3 - Breezula

in Research/Science 4 upvotes 1 year ago

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.

in Treatment 25 upvotes 4 weeks ago

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov

in Research/Science 26 upvotes 1 year ago

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

community Alfatradiol is a topical 5AR inhibitor that this study shows is effective in stopping hair loss without sides. It can be bought OTC in Europe right now. Thoughts?

11 upvotes 8 years ago

Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.

View more "cosmo pharmaceuticals" in community →